Future directions and treatment strategies for head and neck squamous cell carcinomas

Translational Research

Volumn 160, Issue 3, 2012, Pages 167-177

  Wise Draper, Trisha M ^a,b   Draper, David J ^c   Gutkind, J Silvio ^d   Molinolo, Alfredo A ^d   Wikenheiser Brokamp, Kathryn A ^a   Wells, Susanne I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEK PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FLUCYTOSINE; FLUOROURACIL; FLUOROURIDINE; HYDROXYUREA; IRINOTECAN; KH 901; LAPATINIB; LONTUCIREV; NIMOTUZUMAB; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; PANITUMUMAB; PROTEIN; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALUTUMUMAB;

ADENOVIRUS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CERVICAL LYMPH NODE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER ASSISTED TOMOGRAPHY; CYTOLYSIS; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; GENE DELETION; GENETIC ASSOCIATION; GENOTOXICITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; INFECTION RATE; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FAILURE; LARYNX; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NECK DISSECTION; NEUTROPENIA; NONHUMAN; ODYNOPHAGIA; ONCOLYTIC VIROTHERAPY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTO ONCOGENE; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; ROBOTICS; SINGLE DRUG DOSE; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; WART VIRUS; XEROSTOMIA;

EID: 84865759217     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.02.002     Document Type: Review

References (83)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. D.M. Parkin, and C.S. Muir Cancer incidence in five continents. Comparability and quality of data IARC Sci Publ 120 1992 45 173
3. S.F. Hall, P.A. Groome, and D. Rothwell The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck Head Neck 22 2000 317 322 (Pubitemid 30413294)
4. A.A. Forastiere, K.K. Ang, and D. Brizel National Comprehensive Cancer Network, Head and neck cancers J Natl Compr Canc Netw 6 2008 646 695
5. K.A. Workowski, and S.M. Berman Sexually transmitted diseases treatment guidelines, 2006 MMWR Recomm Rep 55 RR-11 2006 1 94
6. F.X. Bosch, A. Lorincz, N. Munoz, C.J. Meijer, and K.V. Shah The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 2002 244 265 (Pubitemid 34293391)
7. M. Pett, and N. Coleman Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 212 2007 356 367 (Pubitemid 47099012)
8. C. Fakhry, and M.L. Gillison Clinical implications of human papillomavirus in head and neck cancers J Clin Oncol 24 2006 2606 2611 (Pubitemid 46622080)
9. A.R. Kreimer, G.M. Clifford, P. Boyle, and S. Franceschi Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review Cancer Epidemiol Biomarkers Prev 14 2005 467 475 (Pubitemid 40270113)
10. C. Scully Oral squamous cell carcinoma: from an hypothesis about a virus, to concern about possible sexual transmission Oral Oncol 38 2002 227 234 (Pubitemid 34442543)
11. A. Psyrri, and D. DiMaio Human papillomavirus in cervical and head-and-neck cancer Nat Clin Pract 5 2008 24 31 (Pubitemid 351512426)
12. L. Vidal, and M.L. Gillison Human papillomavirus in HNSCC: recognition of a distinct disease type Hematol Oncol Clin North Am 22 2008 1125 1142 vii
13. M. von Lindern, M. Fornerod, S. van Baal, and M. Jaegle The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, DEK and CAN, and the expression of a chimeric, leukemia-specific DEK-CAN mRNA Mol Cell Biol 12 1992 1687 1697
14. M. Orlic, C.E. Spencer, L. Wang, and B.L. Gallie Expression analysis of 6p22 genomic gain in retinoblastoma Genes Chromosomes Cancer 45 2006 72 82 (Pubitemid 46930863)
15. Q. Wu, M.J. Hoffmann, F.H. Hartmann, and W.A. Schulz Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer Mol Cancer 4 2005 16
16. P. Secchiero, R. Voltan, M.G. di Iasio, E. Melloni, M. Tiribelli, and G. Zauli The oncogene DEK promotes leukemic cell survival and is downregulated by both nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells Clin Cancer Res 16 2010 1824 1833
17. T. Shibata, A. Kokubu, and M. Miyamoto DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung Oncogene 29 2010 4671 4681
18. M.S. Khodadoust, M. Verhaegen, and F. Kappes Melanoma proliferation and chemoresistance controlled by the DEK oncogene Cancer Res 69 2009 6405 6413
19. Q. Wu, Z. Li, H. Lin, L. Han, S. Liu, and Z. Lin DEK overexpression in uterine cervical cancers Pathol Int 58 2008 378 382 (Pubitemid 351677540)
20. M.C. Abba, H. Sun, and K.A. Hawkins Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status Mol Cancer Res 5 2007 881 890 (Pubitemid 47416665)
21. T.M. Wise-Draper, H.V. Allen, E.E. Jones, K.B. Habash, H. Matsuo, and S.I. Wells Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions Mol Cell Biol 26 2006 7506 7519 (Pubitemid 44547701)
22. T.M. Wise-Draper, H.V. Allen, and M.N. Thobe The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7 J Virol 79 2005 14309 14317 (Pubitemid 41552728)
23. A.A. Molinolo, S.M. Hewitt, and P. Amornphimoltham Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative Clin Cancer Res 13 2007 4964 4973 (Pubitemid 47502060)
24. K.K. Ang Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes Oncologist 13 2008 899 910
25. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 2006 843 854 (Pubitemid 44292807)
26. K.K. Fu, T.F. Pajak, and A. Trotti A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16 (Pubitemid 30488207)
27. W.M. Mendenhall, R.J. Amdur, and J.R. Palta Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls J Clin Oncol 24 2006 2618 2623 (Pubitemid 46622082)
28. J. Bernier, J.S. Cooper, and T.F. Pajak Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Head Neck 27 2005 843 850 (Pubitemid 41395696)
29. F. Denis, P. Garaud, and E. Bardet Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma J Clin Oncol 22 2004 69 76 (Pubitemid 41095116)
30. C.H. Chung, K. Ely, and L. McGavran Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas J Clin Oncol 24 2006 4170 4176 (Pubitemid 46622295)
31. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
32. B. Burtness, M.A. Goldwasser, W. Flood, B. Mattar, and A.A. Forastiere Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study J Clin Oncol 23 2005 8646 8654 (Pubitemid 46211507)
33. J.B. Vermorken, E. Remenar, and C. van Herpen Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 2007 1695 1704 (Pubitemid 350005151)
34. J.P. Machiels, and S. Schmitz Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy Curr Opin Oncol 23 2011 241 248
35. J.M. Del Campo, R. Hitt, and P. Sebastian Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck Br J Cancer 105 2011 618 627
36. J.K. Salama, D.J. Haraf, and K.M. Stenson A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers Ann Oncol 22 2011 2304 2309
37. J.P. Machiels, S. Henry, and S. Zanetta Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 J Clin Oncol 28 2010 21 28
38. S.K. Williamson, J. Moon, and C.H. Huang Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420 J Clin Oncol 28 2010 3330 3335
39. C. Elser, L.L. Siu, and E. Winquist Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773 (Pubitemid 47372619)
40. C.H. Chung, J. Aulino, and N.J. Muldowney Nuclear factor-κB pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ann Oncol 21 2010 864 870
41. N. Stransky, A.M. Egloff, and A.D. Tward The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
42. N. Agrawal, M.J. Frederick, and C.R. Pickering Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 2011 1154 1157
43. R.H. Brakenhoff Cancer: another NOTCH for cancer Science 333 2011 1102 1103
44. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
45. R. Czerninski, P. Amornphimoltham, V. Patel, A.A. Molinolo, and J.S. Gutkind Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model Cancer Prev Res (Phila) 2 2009 27 36
46. V. Patel, C.A. Marsh, and R.T. Dorsam Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer Cancer Res 71 2011 7103 7112
47. A.R. Raimondi, A. Molinolo, and J.S. Gutkind Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model Cancer Res 69 2009 4159 4166
48. F. McCormick Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 1 2001 130 141 (Pubitemid 33741888)
49. C.C. O'Shea, L. Johnson, and B. Bagus Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity Cancer Cell 6 2004 611 623 (Pubitemid 40017704)
50. J. Fueyo, C. Gomez-Manzano, and R. Alemany A mutant oncolytic adenovirus targeting the rb pathway produces anti-glioma effect in vivo Oncogene 19 2000 2 12 (Pubitemid 30066345)
51. J.A. Howe, G.W. Demers, and D.E. Johnson Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy Mol Ther 2 2000 485 495
52. J.R. Bischoff, D.H. Kirn, and A. Williams An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 Oct 18 373 376 (Pubitemid 26353341)
53. Y. Shen, G. Kitzes, J.A. Nye, A. Fattaey, and T. Hermiston Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein J Virol 75 2001 4297 4307 (Pubitemid 32410142)
54. H.J. van Zeeburg, A. Huizenga, and A. Brink Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions Gene Ther 17 2010 1517 1524
55. J.D. Dias, K. Guse, and P. Nokisalmi Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures Eur J Cancer 46 2010 625 635
56. J.D. Dias, I. Liikanen, and K. Guse Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1 Clin Cancer Res 16 2010 2540 2549
57. J. Nemunaitis, F. Khuri, and I. Ganly Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 19 2001 289 298 (Pubitemid 32112839)
58. J. Chang, X. Zhao, and X. Wu A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers Cancer Biol Ther 8 2009 676 682
59. A.T. Mace, I. Ganly, D.S. Soutar, and S.M. Brown Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma Head Neck 30 2008 1045 1051
60. K.J. Harrington, M. Hingorani, and M.A. Tanay Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck Clin Cancer Res 16 2010 4005 4015
61. M.G. Isles, C. McConkey, and H.M. Mehanna A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy Clin Otolaryngol 33 2008 210 222 (Pubitemid 351799005)
62. H.H. Wong, N.R. Lemoine, and Y. Wang Oncolytic viruses for cancer therapy: overcoming the obstacles Viruses 2 2010 78 106
63. M. Sanchez-Carbayo, N.D. Socci, and J.J. Lozano Gene discovery in bladder cancer progression using cDNA microarrays Am J Pathol 163 2003 505 516 (Pubitemid 36909413)
64. T.M. Wise-Draper, R.A. Mintz-Cole, and T.A. Morris Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo Cancer Res 69 2009 1792 1799
65. M.S. Carro, F.M. Spiga, and M. Quarto DEK expression is controlled by E2F and deregulated in diverse tumor types Cell Cycle 5 2006 1202 1207 (Pubitemid 43845381)
66. L.M. Privette Vinnedge, R. McClaine, P.K. Wagh, K.A. Wikenheiser-Brokamp, S.E. Waltz, and S.I. Wells The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer Oncogene 30 2011 2741 2752
67. F. Kappes, M.S. Khodadoust, and L. Yu DEK expression in melanocytic lesions Hum Pathol 42 2011 932 938
68. T.M. Wise-Draper, R.J. Morreale, and T.A. Morris DEK proto-oncogene expression interferes with the normal epithelial differentiation program Am J Pathol 174 2009 71 81
69. G.M. Kavanaugh, T.M. Wise-Draper, and R.J. Morreale The human DEK oncogene regulates DNA damage response signaling and repair Nucleic Acids Res 39 2011 7465 7476
70. F. Kappes, J. Fahrer, and M.S. Khodadoust DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress Molecular Cellular Biol 28 2008 3245 3257 (Pubitemid 351657089)
71. E. Riveiro-Falkenbach, and M.S. Soengas Control of tumorigenesis and chemoresistance by the DEK oncogene Clin Cancer Res 16 2010 2932 2938
72. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111 (Pubitemid 33041634)
73. M.E. Prince, and L.E. Ailles Cancer stem cells in head and neck squamous cell cancer J Clin Oncol 26 2008 2871 2875
74. C. Oancea, B. Ruster, R. Henschler, E. Puccetti, and M. Ruthardt The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation Leukemia 24 2010 1910 1919
75. N. Mor-Vaknin, A. Punturieri, and K. Sitwala The DEK nuclear autoantigen is a secreted chemotactic factor Mol Cell Biol 26 2006 9484 9496 (Pubitemid 44904440)
76. F. Kappes, T. Waldmann, and V. Mathew The DEK oncoprotein is a su(var) that is essential to heterochromatin integrity Genes Dev 25 2011 673 678
77. X.H. Tang, B. Knudsen, D. Bemis, S. Tickoo, and L.J. Gudas Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice Clin Cancer Res 10 1 Pt 1 2004 301 313 (Pubitemid 38114193)
78. L. Vitale-Cross, R. Czerninski, P. Amornphimoltham, V. Patel, A.A. Molinolo, and J.S. Gutkind Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer Cancer Prev Res (Phila) 2 2009 419 422
79. K. Strati, H.C. Pitot, and P.F. Lambert Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model Proc Natl Acad Sci U S A 103 2006 14152 14157 (Pubitemid 44452995)
80. D. Sano, and J.N. Myers Xenograft models of head and neck cancers Head Neck Oncol 1 2009 32
81. R.S. Kerbel Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved Cancer Biol Ther 2 4 Suppl 1 2003 S134 S139
82. C. Simon, A.J. Nemechek, and D. Boyd An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion Laryngoscope 108 11 Pt 1 1998 1686 1691
83. N.P. Reddy, S. Miyamoto, and K. Araki A novel orthotopic mouse model of head and neck cancer with molecular imaging Laryngoscope 121 2011 1202 1207